News

Latest updates from Engimata

The Chamber's Business Connection newsletter is a bi-montly publication inserted into the Pleasanton Weekly on the first Friday of the odd-numbered months. It features business spotlights on members, a column by the board chair, membership anniversaries, ribbon cuttings and more. 
​​​​​​​
Engimata Article (PDF)
Business Connection Newsletter

"Dr. Mitra Mosharraf MBA ’20 CEO of Engimata, Inc. is working to improve vaccine efficiency and enhance vaccine stability. Advice to women entrepreneurs: “Do not be afraid to fail. Failure is just a new starting point that helps us grow until we find the right path.”
Original Post

There is an urgent need for a COVID-19 vaccine. Currently, multiple COVID-19 vaccines are in various stages of development, with Moderna, Pfizer, Sanofi, Johnson & Johnson and AstraZenecca at the frontline. Both Moderna and Pfizer are developing mRNA vaccines that must be stored and transported at -70 °C or -20 °C. This greatly limits their distribution throughout the world because of the complicated and expensive supply chain needed to distribute these vaccines*.

Engimata has focused on development of vaccines that can be transported and stored outside the cold supply chain. We have recently developed a thermostable COVID-19 vaccine that, unlike other vaccines being developed, does not require a complicated cold-chain for transportation and distribution.
​​​​​​​
Vaccine wastage in the supply chain due to temperature fluctuations is a major problem for current vaccines and costs the government and WHO billions of dollars every year. In order to combat COVID-19, it is crucial to overcome transportation barriers and distribute a vaccine across the world.